Based on data from overseas and local case modelling, Rural Ambulance Victoria [RAV] implemented a pilot study of prehospital thrombolysis [PHT] for patients with ST Elevation Myocardial Infarction [STEMI] in the Bendigo region. The purpose of this report is to provide the background to the pilot, describe the PHT model, report the outcome of the single enrolled case and discuss various barriers to PHT implementation.
KeeleyEC, BouraJA, GrinesCL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet2003; 361(9351): 13–20.
2.
Streptokinase in acute myocardial infarction.European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. N Engl J Med1979; 301(15): 797–802.
3.
Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet1986; 1(8478): 397–402.
4.
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet1988; 2(8607): 349–60.
5.
GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction.Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet1990; 336(8707): 65–71.
6.
WhiteHD, NorrisRM, BrownMA, TakayamaM, MaslowskiA, BassNM. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med1987; 317(14): 850–5.
7.
KaragounisL, MorenoF, MenloveRL, IpsenS, AndersonJL. Effects of early thrombolytic therapy (anistreplase versus streptokinase) on enzymatic and electrocardiographic infarct size in acute myocardial infarction. TEAM-2 Investigators. Am J Cardiol1991; 68(9): 848–56.
8.
MaynardC, AlthouseR, OlsufkaM, RitchieJL, DavisKB, KennedyJW. Early versus late hospital arrival for acute myocardial infarction in the western Washington thrombolytic therapy trials. Am J Cardiol1989; 63(18): 1296–300.
9.
SheehanFH, BraunwaldE, CannerP, DodgeHT, GoreJ, Van NattaP. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation1987; 75(4): 817–29.
10.
WestonCF, PennyWJ, JulianDG. Guidelines for the early management of patients with myocardial infarction. British Heart Foundation Working Group. Bmj1994; 308(6931): 767–71.
11.
Guidelines for the management of acute coronary syndromes 2006. Med J Aust2006; 184(8 Suppl): S9–29.
12.
KellyAM, KerrD, PatrickI, WalkerT. Call-to-needle times for thrombolysis in acute myocardial infarction in Victoria. Med J Aust2003; 178(8): 381–5.
13.
MorrisonLJ, VerbeekPR, McDonaldAC, SawadskyBV, CookDJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. Jama2000; 283(20): 2686–92.
14.
StegPG, BonnefoyE, ChabaudS, LapostolleF, DubienPY, CristofiniP. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation2003; 108(23): 2851–6.
15.
DanchinN, BlanchardD, StegPG, SauvalP, HananiaG, GoldsteinPImpact of prehospital thrombolysis for acute myocardial infarction on 1–year outcome: results from the French Nationwide USIC 2000 Registry. Circulation2004; 110(14): 1909–15.
